Mechanism of selective packaging of primer tRNALys3 by HIV-1
HIV-1选择性包装引物tRNALys3的机制
基本信息
- 批准号:10258167
- 负责人:
- 金额:$ 21.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-22 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAffinityAmino Acyl-tRNA SynthetasesAminoacylationAnisotropyAnti-Retroviral AgentsBindingBiochemicalBiological AssayBiologyC-terminalCalorimetryCapsid ProteinsCatalytic DomainCellsChargeChemicalsComplexCoupledCryoelectron MicroscopyCrystallizationDataDependenceDevelopmentDissectionDrug resistanceEMSAElectron MicroscopyElectrophoretic Mobility Shift AssayEnzymesEventFluorescenceFluorescence AnisotropyGoalsHIVHIV-1IndividualInfectionKineticsKnowledgeLife Cycle StagesLysine-Specific tRNALysine-tRNA LigaseMeasuresModelingMolecularMolecular Sieve ChromatographyNegative StainingNon-Small-Cell Lung CarcinomaPharmaceutical PreparationsPhosphorylationPlayProcessPublic HealthRecording of previous eventsReportingResearchResolutionReverse TranscriptionRoleSP1 geneStructureTestingTitrationsTranscriptional RegulationTransfer RNAVaccinesValidationViral GenomeViral Reverse TranscriptionVirionWorkX-Ray Crystallographybasebiophysical techniquescomparativecrosslinkdesigndrug developmentexperimental studyflexibilityinsightlight scatteringmutantnew therapeutic targetnovelpandemic diseaseparticlepol Gene Productsrecruitresistance mutationscreeningsuccesstherapeutic development
项目摘要
Project Summary:
HIV-1 and the AIDS pandemic remains a significant threat to public health. The lack of a vaccine against
HIV-1 and the looming specter of drug-resistant mutations urge the search for novel drug targets. A critical step
of the HIV-1 life cycle is the selective packaging of host tRNALys1,2,3 during virion assembly, wherein the tRNALys3
isoacceptor is later used as a primer for initiating reverse transcription. This phenomenon of selective tRNALys
packaging by HIV-1 was discovered nearly three decades ago, but the structural and molecular details of this
event remain elusive. LysRS (lysyl-tRNA synthetase), the cellular enzyme for aminoacylation of tRNALys3, has
been shown to play a crucial role in tRNALys packaging by HIV-1. LysRS is predominantly sequestered as part
of the multi-tRNA synthetase complex (MSC) but a catalytically inactive S207 phosphorylated (pS207) pool of
cellular LysRS is released from the MSC upon HIV-1 infection. HIV-1 Gag plays the primary role in LysRS and
tRNALys3 packaging. The current model postulates that tRNALys3 is indirectly packaged by HIV-1 Gag via an
interaction between its capsid protein (CA) and the catalytic domain of LysRS. However, this model is based
primarily on studies carried out with unmodified LysRS in the absence of tRNALys3 and our preliminary data
contradicts this model. HIV-1 has been shown to selectively package uncharged tRNALys3 over charged tRNALys3
and pS207-LysRS has been proposed to play a role in this packaging bias. There is no high-resolution structural
information available on pS207-LysRS to provide a mechanistic basis for its lack of aminoacylation activity, its
interactions with HIV-1 Gag, or the non-canonical functions it performs. The lack of any structural information on
how HIV-1 Gag recruits LysRS and tRNALys3 has precluded targeting this step for drug development and the
proposed work will address this knowledge gap. The overall goal of this research is to establish a mechanistic
and structural basis for selective packaging of uncharged tRNALys3 by HIV-1. In Aim 1, we will carry out a
comprehensive comparative characterization of the HIV-1 factors reported to bind LysRS and tRNALys3 using
qualitative and quantitative biochemical and biophysical techniques. The comparative molecular dissection will
allow us to establish the minimal core components of the tRNALys3 packaging complex. We will use a
phosphomimetic mutant of LysRS (LysRSS207D) to study the role of pS207-LysRS in selective packaging of
uncharged tRNALys3 and study the kinetics of the ternary tRNALys3 packaging complex to probe any cooperativity
in complex formation. The thorough biochemical characterization will help establish a stable ternary tRNALys3
packaging complex for structural studies. In Aim 2, we will use a parallel two-pronged approach of single particle
cryo-EM and X-ray crystallography to determine a high-resolution structure of the ternary tRNALys3 packaging
complex and validate our structural insights using cell-based pull-down, tRNALys packaging, and HIV-1 infectivity
assays. Insights gained from this study will elucidate a critical yet untapped aspect of HIV biology for the design
and development of novel antiretroviral drugs.
项目概要:
HIV-1和艾滋病流行病仍然是对公共卫生的重大威胁。由于缺乏疫苗,
HIV-1和抗药性突变的阴影迫使人们寻找新的药物靶点。一个关键步骤
HIV-1生命周期的一个重要特征是在病毒体组装期间宿主tRNALys 1、2、3的选择性包装,其中tRNALys 3
随后将同种受体用作启动逆转录的引物。这种选择性tRNALys的现象
HIV-1的包装是在近三十年前发现的,但这种包装的结构和分子细节
事件仍然难以捉摸。LysRS(赖氨酰-tRNA合成酶)是tRNALys 3氨酰化的细胞酶,具有
已经显示在HIV-1包装tRNALys中起关键作用。LysRS主要作为一种
的多tRNA合成酶复合物(MSC),但无催化活性的S207磷酸化(pS207)库,
细胞LysRS在HIV-1感染时从MSC释放。HIV-1 Gag在LysRS中起主要作用,
tRNALys 3包装。目前的模型假设tRNALys 3是由HIV-1 Gag通过一个
其衣壳蛋白(CA)和LysRS的催化结构域之间的相互作用。然而,该模型基于
主要是在tRNALys 3不存在的情况下用未修饰的LysRS进行的研究和我们的初步数据
与这个模型相矛盾。已经显示HIV-1选择性地包装不带电荷的tRNALys 3而不是带电荷的tRNALys 3
而pS207-LysRS被认为在这种包装偏倚中起作用。没有高分辨率的结构
关于pS207-LysRS的可用信息提供了其缺乏氨酰化活性的机理基础,其
与HIV-1 Gag的相互作用,或其执行的非规范功能。缺乏任何结构性信息,
HIV-1 Gag如何招募LysRS和tRNALys 3已经排除了药物开发的这一步骤,
拟议的工作将弥补这一知识差距。本研究的总体目标是建立一个机制,
以及HIV-1选择性包装不带电荷的tRNALys 3的结构基础。在目标1中,我们将实施
使用以下方法对报告结合LysRS和tRNALys 3的HIV-1因子进行全面比较表征:
定性和定量生物化学和生物物理技术。比较分子解剖将
允许我们建立tRNALys 3包装复合物的最小核心组分。我们将使用一个
LysRS的磷酸化模拟突变体(LysRSS 207 D),以研究pS207-LysRS在选择性包装
不带电荷的tRNALys 3并研究三元tRNALys 3包装复合物的动力学以探测任何协同性
形成复杂的队形彻底的生化表征将有助于建立稳定的三元tRNALys 3
包装复杂的结构研究。在目标2中,我们将使用单粒子的并行双管齐下的方法
cryo-EM和X射线晶体学,以确定三元tRNALys 3封装的高分辨率结构
使用基于细胞的下拉,tRNALys包装和HIV-1感染性来复杂和验证我们的结构见解
分析。从这项研究中获得的见解将阐明艾滋病毒生物学的一个关键但尚未开发的方面,
和开发新型抗逆转录病毒药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karin M Musier-Forsyth其他文献
Karin M Musier-Forsyth的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karin M Musier-Forsyth', 18)}}的其他基金
Translational quality control by trans-editing domains
通过转编辑域控制翻译质量
- 批准号:
10206957 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
Mechanism of selective packaging of primer tRNALys3 by HIV-1
HIV-1选择性包装引物tRNALys3的机制
- 批准号:
10376353 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
Translational quality control by trans-editing domains
通过转编辑域控制翻译质量
- 批准号:
10406288 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
Translational quality control by trans-editing domains
通过转编辑域控制翻译质量
- 批准号:
10605294 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
Translational quality control by trans-editing domains
通过转编辑域控制翻译质量
- 批准号:
10822416 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
Translational quality control by trans-editing domains
通过转编辑域控制翻译质量
- 批准号:
10580273 - 财政年份:2021
- 资助金额:
$ 21.79万 - 项目类别:
RNA binding and packaging by retroviral Gag proteins
逆转录病毒 Gag 蛋白的 RNA 结合和包装
- 批准号:
10576298 - 财政年份:2020
- 资助金额:
$ 21.79万 - 项目类别:
RNA binding and packaging by retroviral Gag proteins
逆转录病毒 Gag 蛋白的 RNA 结合和包装
- 批准号:
10034983 - 财政年份:2020
- 资助金额:
$ 21.79万 - 项目类别:
RNA binding and packaging by retroviral Gag proteins
逆转录病毒 Gag 蛋白的 RNA 结合和包装
- 批准号:
10347332 - 财政年份:2020
- 资助金额:
$ 21.79万 - 项目类别:
Cellular Factors Critical for Initiation of HIV-1 Reverse Transcriptase
对 HIV-1 逆转录酶启动至关重要的细胞因素
- 批准号:
10393691 - 财政年份:2014
- 资助金额:
$ 21.79万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.79万 - 项目类别:
Research Grant